AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 842
- Registration Number
- NCT00784953
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
A Study on Intima Media Thickness (IMT) in Middle-aged Subjects
Completed
- Conditions
- Atherosclerosis
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00784264
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 57
- Registration Number
- NCT00782574
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Four Dimensions in Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 320
- Registration Number
- NCT00782899
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Antidepressant Incomplete Response Depression
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 364
- Registration Number
- NCT00782964
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-07-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00782314
- Locations
- 🇸🇮
Research Site, Zagorje, Slovenia
Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements
Early Phase 1
Completed
- Conditions
- AtherosclerosisInflammatory Activity in Coronary Arteries
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00783042
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
AZD6765 Severe Major Depressive Disorder (MDD) IV
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 152
- Registration Number
- NCT00781742
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2575
- Registration Number
- NCT00781560
- Locations
- 🇨🇳
Reseearch Site, Ningbo, Zhejiang, China
🇨🇳Research Site, Hangzhou, Zhejiang, China
Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 96
- Registration Number
- NCT00779506
- Locations
- 🇰🇷
Research site, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath